Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Javle

Showing results (91-100 of 99) with videos related to

Pageof 10
Sort By:
You have reached the last page of results.This site can display upto 99 results.
The Lancet. Oncology|May 17, 2020
Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 studyGhassan K Abou-Alfa, Teresa Macarulla, Milind M Javle, et al.
Annals of Surgery|April 7, 2023
Effects of a Pragmatic Home-based Exercise Program Concurrent With Neoadjuvant Therapy on Physical Function of Patients With Pancreatic Cancer: The PancFit Randomized Clinical TrialAn T Ngo-Huang, Nathan H Parker, Lianchun Xiao, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 11, 2022
The clinical landscape of cell-free DNA alterations in 1671 patients with advanced biliary tract cancerJ E Berchuck, F Facchinetti, D F DiToro, et al.
JAMA Oncology|September 23, 2021
Final Overall Survival Efficacy Results of Ivosidenib for Patients With Advanced Cholangiocarcinoma With IDH1 Mutation: The Phase 3 Randomized Clinical ClarIDHy TrialAndrew X Zhu, Teresa Macarulla, Milind M Javle, et al.
Journal of the National Cancer Institute|April 11, 2023
Molecular profiling and treatment pattern differences between intrahepatic and extrahepatic cholangiocarcinomaKristen Spencer, Leontios Pappas, Islam Baiev, et al.
The Lancet. Gastroenterology & Hepatology|March 16, 2025
Software-based versus visual assessment of the minimal ablative margin in patients with liver tumours undergoing percutaneous thermal ablation (COVER-ALL): a randomised phase 2 trialBruno C Odisio, Jessica Albuquerque, Yuan-Mao Lin, et al.
JCO Precision Oncology|August 10, 2023
The Cholangiocarcinoma in the Young (CITY) Study: Tumor Biology, Treatment Patterns, and Survival Outcomes in Adolescent Young Adults With CholangiocarcinomaLeontios Pappas, Islam Baiev, Stephanie Reyes, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 18, 2025
Clinicogenomic Characterization of Primary Sclerosing Cholangitis-Associated Biliary Tract CancersXin Wang, Jaime Ivan Haro-Silerio, Felix Emile Gastonguay Beaudry, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 20, 2024
A model for decoding resistance in precision oncology: acquired resistance to FGFR inhibitors in cholangiocarcinomaL Goyal, D DiToro, F Facchinetti, et al.
Pageof 10

Showing results (91-100 of 99) with videos related to

Sort By:
Pageof 10
You have reached the last page of results.This site can display upto 99 results.
The Lancet. Oncology|May 17, 2020
Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 studyGhassan K Abou-Alfa, Teresa Macarulla, Milind M Javle, et al.
Annals of Surgery|April 7, 2023
Effects of a Pragmatic Home-based Exercise Program Concurrent With Neoadjuvant Therapy on Physical Function of Patients With Pancreatic Cancer: The PancFit Randomized Clinical TrialAn T Ngo-Huang, Nathan H Parker, Lianchun Xiao, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 11, 2022
The clinical landscape of cell-free DNA alterations in 1671 patients with advanced biliary tract cancerJ E Berchuck, F Facchinetti, D F DiToro, et al.
JAMA Oncology|September 23, 2021
Final Overall Survival Efficacy Results of Ivosidenib for Patients With Advanced Cholangiocarcinoma With IDH1 Mutation: The Phase 3 Randomized Clinical ClarIDHy TrialAndrew X Zhu, Teresa Macarulla, Milind M Javle, et al.
Journal of the National Cancer Institute|April 11, 2023
Molecular profiling and treatment pattern differences between intrahepatic and extrahepatic cholangiocarcinomaKristen Spencer, Leontios Pappas, Islam Baiev, et al.
The Lancet. Gastroenterology & Hepatology|March 16, 2025
Software-based versus visual assessment of the minimal ablative margin in patients with liver tumours undergoing percutaneous thermal ablation (COVER-ALL): a randomised phase 2 trialBruno C Odisio, Jessica Albuquerque, Yuan-Mao Lin, et al.
JCO Precision Oncology|August 10, 2023
The Cholangiocarcinoma in the Young (CITY) Study: Tumor Biology, Treatment Patterns, and Survival Outcomes in Adolescent Young Adults With CholangiocarcinomaLeontios Pappas, Islam Baiev, Stephanie Reyes, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 18, 2025
Clinicogenomic Characterization of Primary Sclerosing Cholangitis-Associated Biliary Tract CancersXin Wang, Jaime Ivan Haro-Silerio, Felix Emile Gastonguay Beaudry, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 20, 2024
A model for decoding resistance in precision oncology: acquired resistance to FGFR inhibitors in cholangiocarcinomaL Goyal, D DiToro, F Facchinetti, et al.
Pageof 10